According to the settlement agreement, the proposed biosimilar to Eylea® (aflibercept) can be marketed in the U.S., if approved by the FDA, in the fourth quarter of 2026, or earlier under certain circumstances REYKJAVIK, Iceland and TEL AVIV, Israel, Dec. 19, 2025 (Korea Bizwire) – Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development [...]
TEL AVIV, Israel, Dec. 12, 2025 (Korea Bizwire) – Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its fourth quarter 2025 financial results on Wednesday, January 28, 2026, at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on [...]
Olanzapine long-acting injectable (LAI) has the potential to offer the efficacy of olanzapine in a once-monthly, subcutaneous formulation, for a broad patient population1 Olanzapine LAI is designed to help support real-world adherence and improved stability, with the goal of addressing a critical treatment gap for people living with schizophrenia1 Teva is committed to advancing this [...]
First cohort features 7 real-world challenges across R&D, manufacturing and supply chain, commercial and medical affairs Teva’s first-ever global innovation platform aims to accelerate patient impact and drive business transformation, as part of its Pivot to Growth Strategy Rise will enable startups and tech players worldwide to validate their solutions in real-world settings, scaling impact [...]
In a new cohort of 27 adults from the IMPACT-TD Registry, up to 77% of participants reported improvements in aspects of their lives impacted by tardive dyskinesia (TD) while taking AUSTEDO or AUSTEDO XR Most (85%) participants taking AUSTEDO or AUSTEDO XR in conjunction with their mental health medications reported that their mental health condition [...]
For an accessible version of this Press Release, please visit www.tevapharm.com Teva reports revenues of $4.5 billion in the third quarter of 2025, an increase of 3% year-over-year (YoY) in U.S. dollars or 1% in local currency (LC). Excluding Japan BV in Q3 2024, revenues increased 5% in U.S. dollars or 3% in LC. United [...]
TEL AVIV, Israel, Oct. 31, 2025 (Korea Bizwire) – Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva’s President and CEO, will present at two upcoming investor conferences in November as follows: UBS Global Healthcare Conference Monday, November 10, 2025, at 8:45 A.M. Eastern Time (ET) Jefferies London Healthcare Conference Tuesday, [...]
TEL AVIV, Israel, Sept. 25, 2025 (Korea Bizwire) – Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its third quarter 2025 financial results on Wednesday, November 5, 2025, at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on [...]
Of the 209 patients with tardive dyskinesia (TD) that were surveyed, >94% reported movement improvement once treated with AUSTEDO XR® (deutetrabenazine) extended-release tablets Patients reported high satisfaction (>89%) with AUSTEDO XR, with 96% expressing interest in continuing treatment Almost all (>96%) patients relayed that AUSTEDO XR was easy to take PARSIPPANY, N.J. and TEL AVIV, Israel, [...]
TEL AVIV, Israel, Sept. 16, 2025 (Korea Bizwire) – Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced plans to present data from the completed phase 3 SOLARIS trial at the 2025 Psych Congress Annual Meeting, taking place from September 17 – 21, 2025, in San Diego, California. Teva will also host a conference [...]